Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

NCCN Adds Trastuzumab Deruxtecan, Sacituzumab Govitecan to Guidelines for Advanced Breast Cancer

June 23rd 2022

“Compelling” data support the use of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer and the use of sacituzumab govitecan for patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

EMA Accepts Type II Application for Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

June 22nd 2022

The European Medicines Agency has validated a Type II Variation application for trastuzumab deruxtecan as monotherapy for adults with unresectable or metastatic HER2-low breast cancer.

Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen

June 22nd 2022

Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.

PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy

June 22nd 2022

Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.

Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer

June 22nd 2022

Shared insight on how best to select frontline therapy, alone or in combination, for patients with HR+/HER2- mBC.

Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC

June 22nd 2022

A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.

Dr. George on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 19th 2022

Mridula George, MD, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial in breast cancer.

Hormone Therapies, ADCs Elicit Long-Term Survival Benefits Across Breast Cancer Subtypes

June 17th 2022

Novel combinations with CDK4/6 inhibitors, antibody-drug conjugates, and oral selective estrogen receptor degraders are rapidly changing the treatment paradigm in hormone receptor–positive and HER2-positive breast cancer.

Dr. George on the Background of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 16th 2022

Mridula George, MD, discusses the background of the phase 3 DESTINY-Breast04 trial in breast cancer.

HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium

June 15th 2022

Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.

Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan

June 15th 2022

Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.

Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer

June 15th 2022

Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.

Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer

June 15th 2022

Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.

Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer

June 14th 2022

Nancy U. Lin, MD, discusses the advantage of the oral selective estrogen receptor degrader, elacestrant, in ESR1-mutated breast cancers.

Dr. Hamilton on the EMERALD Trial in ER-Positive/HER2-Negative Breast Cancer

June 14th 2022

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.

Ueno Underscores the Importance of Accurate Diagnoses and Novel Treatments in IBC

June 13th 2022

Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the current ongoing research he’s eager to see reported.

Optimizing Treatment Strategies in Breast Cancer: Q&A

June 8th 2022

Fielding questions from their live audience, Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, discuss optimal selection of therapy for patients with breast cancer.

Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy

June 8th 2022

Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.

Tucatinib Plus First-Line Maintenance Under Exploration in Metastatic HER2+ Breast Cancer

June 8th 2022

Tucatinib plus first-line standard-of-care maintenance therapy with trastuzumab and pertuzumab is being investigated for its ability to improve progression-free survival and maintain health-related quality of life in patients with HER2-positive metastatic breast cancer.

Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases

June 8th 2022

Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.